Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas - PubMed (original) (raw)
Comparative Study
Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas
Karsten Münstedt et al. Cancer Invest. 2004.
Abstract
Purpose: The decision concerning adjuvant therapy remains difficult in patients with very early stage ovarian carcinomas [Fédération Internationale de Gynécologie et d' Obstétrique (FIGO) Ia/b]. Therefore, we compared the MIB1-determined tumor growth fraction in archival tumor tissue with tumor recurrence and outcome of disease, and in relationship to other stages and clinical and morphological findings.
Patients and methods: Ninety-two patients were followed in early stages of ovarian carcinomas (FIGO I and II) with no tumor residuals and were analyzed for tumor recurrences and long-term overall survival (mean 6.0 years, median 5.5). Fifty-eight patients had stage I tumors, among these were 38 in the sub-stages Ia/b. Tumor growth fraction (MIB1) in tissues from primary surgery was compared with the status of patients and disease, histology, and immunohistochemistry for carcinoembryonic antigen (CEA), CA125, CA153, steroid hormone receptors, and angiogenesis (chisquare test, Kaplan-Meier and discriminant analyses).
Results: Tumor-associated deaths occurred in 27 cases, tumor recurrences occurred in 35 cases. In contrast to the advanced stages of disease, the MIB1-determined tumor growth fraction outweighted all other parameters in the prediction of the course of disease (p < 0.001), followed by tumor grading (p = 0.001) and FIGO-substages (p = 0.026) in this retrospective study. Particularly in the very early stages, MIB1 predicted tumor recurrences in 84% of the cases (p < 0.001). Recurrences were not observed below a tumor growth fraction of 10% but prevailed in cases of more than 15%.
Conclusion: Our data suggest MIB1 as an interesting additional tool for the decision of adjuvant therapy in patients with very early stages of ovarian carcinomas, which should be tested in prospective trials.
Similar articles
- THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A, Tamiolakis D, Matalliotaki C, Karvela-Kalogeraki I, Karvelas-Kalogerakis M, Segredakis J, Sinatkas V, Matalliotakis I. Kalogeraki A, et al. Rev Med Chir Soc Med Nat Iasi. 2015 Apr-Jun;119(2):454-60. Rev Med Chir Soc Med Nat Iasi. 2015. PMID: 26204652 - [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK, Zhang HT, Sun YC, Wu LY. Ma SK, et al. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):690-4. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173912 Chinese. - The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I, Sorbe B, Seidal T. Skirnisdóttir I, et al. Int J Gynecol Cancer. 2001 Mar-Apr;11(2):119-29. doi: 10.1046/j.1525-1438.2001.011002119.x. Int J Gynecol Cancer. 2001. PMID: 11328410 - Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature.
Auranen A, Sundström J, Ijäs J, Grénman S. Auranen A, et al. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1011-8. doi: 10.1111/j.1525-1438.2007.00914.x. Epub 2007 Mar 21. Int J Gynecol Cancer. 2007. PMID: 17374124 Review.
Cited by
- The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression.
Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, Martin D, Becker S, Strebhardt K. Rödel F, et al. Front Oncol. 2020 Oct 7;10:558932. doi: 10.3389/fonc.2020.558932. eCollection 2020. Front Oncol. 2020. PMID: 33117692 Free PMC article. - Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Köbel M, et al. PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232. PLoS Med. 2008. PMID: 19053170 Free PMC article. - Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma.
Mahadevappa A, Krishna SM, Vimala MG. Mahadevappa A, et al. J Clin Diagn Res. 2017 Feb;11(2):EC08-EC12. doi: 10.7860/JCDR/2017/24350.9381. Epub 2017 Feb 1. J Clin Diagn Res. 2017. PMID: 28384868 Free PMC article. - Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Grindstad T, Movik I, Dønnem T, Bremnes R, Busund LT. Richardsen E, et al. PLoS One. 2017 Nov 15;12(11):e0186852. doi: 10.1371/journal.pone.0186852. eCollection 2017. PLoS One. 2017. PMID: 29141018 Free PMC article. - Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H, Cai Q, Godwin AK, Zhang R. Li H, et al. Mol Cancer Res. 2010 Dec;8(12):1610-8. doi: 10.1158/1541-7786.MCR-10-0398. Epub 2010 Nov 29. Mol Cancer Res. 2010. PMID: 21115743 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous